JP2022527359A - 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤 - Google Patents

媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤 Download PDF

Info

Publication number
JP2022527359A
JP2022527359A JP2021559187A JP2021559187A JP2022527359A JP 2022527359 A JP2022527359 A JP 2022527359A JP 2021559187 A JP2021559187 A JP 2021559187A JP 2021559187 A JP2021559187 A JP 2021559187A JP 2022527359 A JP2022527359 A JP 2022527359A
Authority
JP
Japan
Prior art keywords
isoxazoline
parasite
sufficient
malaria
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527359A5 (cg-RX-API-DMAC7.html
Inventor
ボバック ロバート アザミアン
ダグラス マイケル アッカーマン
クリストファー スタイヴァーズ
ショーン ディー. ヒッコク
Original Assignee
ターサス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターサス ファーマシューティカルズ, インコーポレイテッド filed Critical ターサス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2022527359A publication Critical patent/JP2022527359A/ja
Publication of JP2022527359A5 publication Critical patent/JP2022527359A5/ja
Priority to JP2026029152A priority Critical patent/JP2026083151A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021559187A 2019-04-04 2020-04-03 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤 Pending JP2022527359A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026029152A JP2026083151A (ja) 2019-04-04 2026-02-26 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829573P 2019-04-04 2019-04-04
US62/829,573 2019-04-04
PCT/IB2020/053229 WO2020202111A1 (en) 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026029152A Division JP2026083151A (ja) 2019-04-04 2026-02-26 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤

Publications (2)

Publication Number Publication Date
JP2022527359A true JP2022527359A (ja) 2022-06-01
JP2022527359A5 JP2022527359A5 (cg-RX-API-DMAC7.html) 2023-04-10

Family

ID=72667108

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559187A Pending JP2022527359A (ja) 2019-04-04 2020-04-03 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤
JP2026029152A Pending JP2026083151A (ja) 2019-04-04 2026-02-26 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026029152A Pending JP2026083151A (ja) 2019-04-04 2026-02-26 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤

Country Status (11)

Country Link
US (2) US20220160682A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527359A (cg-RX-API-DMAC7.html)
KR (1) KR20220054241A (cg-RX-API-DMAC7.html)
CN (1) CN113993518A (cg-RX-API-DMAC7.html)
AU (2) AU2020251960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019931A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136042A1 (cg-RX-API-DMAC7.html)
IL (1) IL286914A (cg-RX-API-DMAC7.html)
MX (1) MX2021012188A (cg-RX-API-DMAC7.html)
WO (1) WO2020202111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US12502377B2 (en) * 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2022079496A1 (en) * 2020-10-13 2022-04-21 Menschlich Healthcare Opc Private Limited A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
CN112294793B (zh) * 2020-10-21 2022-03-22 青岛海洋生物医药研究院股份有限公司 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
WO2022130031A1 (en) * 2020-12-17 2022-06-23 Chander Mohan Negi A pharmaceutical composition of nitazoxanide and mefloquine and method thereof
CN118420621A (zh) * 2021-02-07 2024-08-02 南京知和医药科技有限公司 一种磺酰胺类多环化合物及其制备方法与用途
US20250318529A1 (en) * 2022-05-16 2025-10-16 Syngenta Crop Protection Ag Method for mosquito control
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US20240366572A1 (en) * 2023-05-07 2024-11-07 Michael Farber Isoxazoline complexes and compositions thereof
US11903962B1 (en) * 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266628A1 (en) * 2009-04-14 2010-10-21 Majid Razzak Macrocyclic lactone combination compositions, vaccines and methods for producing same
JP2010536733A (ja) * 2007-08-17 2010-12-02 インターベツト・インターナシヨナル・ベー・ベー イソオキサゾリン組成物および駆虫薬としてのそれらの使用
WO2018081733A1 (en) * 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051106A1 (en) * 2018-09-05 2020-03-12 Zoetis Services Llc Palatable antiparasitic formulations
BR112022000982A2 (pt) * 2019-07-22 2022-03-08 Intervet Int Bv Forma de dosagem veterinária mastigável macia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536733A (ja) * 2007-08-17 2010-12-02 インターベツト・インターナシヨナル・ベー・ベー イソオキサゾリン組成物および駆虫薬としてのそれらの使用
US20100266628A1 (en) * 2009-04-14 2010-10-21 Majid Razzak Macrocyclic lactone combination compositions, vaccines and methods for producing same
WO2018081733A1 (en) * 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission

Also Published As

Publication number Publication date
US20220160682A1 (en) 2022-05-26
AU2020251960A1 (en) 2021-11-11
WO2020202111A1 (en) 2020-10-08
CN113993518A (zh) 2022-01-28
AU2026205483A1 (en) 2026-07-30
MX2021012188A (es) 2022-02-11
CA3136042A1 (en) 2020-10-08
EP3946325A1 (en) 2022-02-09
KR20220054241A (ko) 2022-05-02
US20230218584A1 (en) 2023-07-13
IL286914A (en) 2021-10-31
JP2026083151A (ja) 2026-05-19
BR112021019931A2 (pt) 2021-12-07
EP3946325A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
JP2026083151A (ja) 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤
ES2417157T3 (es) Composiciones de isoxazolina y su uso como antiparasitarios
KR20100080516A (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
KR19980703420A (ko) 지도부딘, 1592u89 및 3tc 또는 ftc의 상승적 배합물
CN110167540A (zh) 用于预防媒介传播疾病的传播的方法和组合物
US20260108498A1 (en) Method of eradicating ticks that attach to humans using lotilaner formulations
US20230233538A1 (en) Composition for treating coronavirus disease-19, comprising phenanthroindolizidine and phenanthroquinolizidine alkaloid derivatives, optical isomer thereof, or pharmaceutically acceptable salts thereof as active ingredient
KR20200050565A (ko) 셀라멕틴을 포함하는 구충제 조성물
KR20230018351A (ko) 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물
US20190142817A1 (en) Compositions and methods for drug sensitization of parasites
JP7274479B2 (ja) 寄生虫の寄生を治療するためのモキシデクチンを含有する組成物
CN102711730B (zh) 用于内部控制或治疗马类胃蝇幼虫的方法
HK40066895A (en) Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
RU2279874C9 (ru) Препарат для профилактики и лечения гельминтозов лошадей
JP2015523388A (ja) 外部寄生虫撲滅薬スピノサドを用いてネコを治療するための単回用量経口製剤および方法
AU764265B2 (en) Viral treatment
US20250204555A1 (en) Feed and methods for controlling intestinal tract parasitic worm infections in mammals
CN101987108A (zh) 一种驱除动物体内外寄生虫的复方注射剂及其制备方法
KR20260008099A (ko) 하이드록시-피롤론의 면역학
WO2025136126A1 (es) Composición oral en forma de gel bioadhesivo a base de isoxazolina
JPH06502405A (ja) イヌの寄生虫処理用アベルメクチンおよびミルベマイシン
NZ537760A (en) Worming formulations comprising a macrocyclic lactone and piperonyl butoxide
KR100903287B1 (ko) 7-에톡시쿠마린을 유효성분으로 함유하는 톡소플라즈마증의예방 및 치료용 조성물
HK40114059A (zh) α-1062用於治疗创伤性脑损伤
CN121422046A (zh) 核苷类化合物在制备抗克里米亚-刚果出血热病毒感染药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724